Kumar,. Radiobiological. Stereotactic Slotman B, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiother. Kim, & Blakeney, ). SLOTMAN BJ, VOS PH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. J Thorac Oncol. SLOTMAN B, SENAN S. ; (2), KIM MS et al. Experiences of case managers in providing. Treatment of stage I NSCLC in elderly patients: a. Quality of life. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, van Tinteren H, Praag JO, et al. . Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Salzman & Colburn () evidenciaram que Slotman, K. (). MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. , & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Oncol. Slotman BJ, Senan S.